Companies: 49,246 Total Market Cap: 132591774254860.43

ALK-Abelló A/S

LON-0OIR
Biological Products, Except Diagnostic Substances
Rank #2886
Market Cap 5.69 B
Volume 2,669
Price 226.45
Change (%) 1.74%
Country or region Denmark Denmark

ALK-Abelló A/S's latest marketcap:

5.69 B

As of 05/20/2025, ALK-Abelló A/S's market capitalization has reached $5.69 B. According to our data, ALK-Abelló A/S is the 2886th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 5.69 B
Revenue (ttm) 853.68 M
Net Income (ttm) 140.14 M
Shares Out 0
EPS (ttm) 0.63
Forward PE 30.71
Ex-Dividend Date n/a
Earnings Date 05/06/2025
Market Cap Chart
Data Updated: 05/20/2025

ALK-Abelló A/S's yearly market capitalization.

ALK-Abelló A/S has seen its market value grow from £3.31 B to £4.27 B since 2020, representing a total increase of 28.82% and an annual compound growth rate (CAGR) of 5.94%.
Date Market Cap Change (%)
05/20/2025 £4.27 B 8.1%
12/30/2024 £3.91 B 50.18%
12/29/2023 £2.61 B 2.98%
12/30/2022 £2.53 B -40.43%
12/30/2021 £4.25 B 28.17%
12/30/2020 £3.31 B

Company Profile

About ALK-Abelló A/S

ALK-Abelló A/S is a global leader in allergy solutions, operating across Europe, North America, and internationally. Founded in 1923 and headquartered in Hørsholm, Denmark, the company specializes in innovative treatments for allergic conditions.

Product Portfolio

The company offers a range of allergy immunotherapy products, including:

  • GRAZAX/GRASTEK – Grass pollen allergy tablet
  • RAGWITEK/RAGWIZAX – Ragweed allergy treatment
  • ACARIZAX/ODACTRA – House dust mite allergy therapy
  • MITICURE – Treatment for house dust mite-induced allergy
  • CEDARCURE – Japanese cedar pollen allergy solution
  • ITULAZAX/ITULATEK – Food allergy immunotherapy

Treatment Solutions

ALK-Abelló provides allergy immunotherapy in multiple forms:

  • Injections
  • Sublingual drops
  • Tablets

These treatments target allergies caused by house dust mites, grass and tree pollen, ragweed, Japanese cedar, and food allergens.

Consumer Healthcare & Digital Solutions

The company offers a Digital eco-system, a platform designed to:

  • Engage with allergy sufferers throughout their treatment journey
  • Provide tools and e-commerce solutions for support and relief
  • Simplify access to allergy immunotherapy treatments

Diagnostic & Emergency Solutions

ALK-Abelló also delivers:

  • Diagnostic allergy testing via skin prick or blood tests
  • Emergency treatments such as adrenaline injections for life-threatening allergic reactions (anaphylaxis)

Strategic Collaborations

The company partners with Torii Pharmaceutical Co., Ltd. to develop and distribute key allergy treatments, including GRAZAX, CEDARCURE, and MITICURE.

Frequently Asked Questions

As of 05/20/2025, ALK-Abelló A/S (including the parent company, if applicable) has an estimated market capitalization of $5.69 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.

ALK-Abelló A/S global market capitalization ranking is approximately 2886 as of 05/20/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

Stock Detail

Country or region Denmark
Founded 1923
IPO Date n/a
Employees 2,753
CEO Peter Halling
Sector
Industry Biological Products, Except Diagnostic Substances
Address Bøge Allé 6-8
Hørsholm, 2970
Denmark
Website https://www.alk.net
People Also Watch
LON-0MTD
409.69 1.74%
KOSDAQ-950160
26.20 1.74%
FRA-BIO
47.83 1.74%
Caregen
24.21 1.74%